- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 03 July 2013 00:00
- Written by Gregory Fowler
A majority of participants in an extension of the iPrEx pre-exposure prophylaxis (PrEP) trial said they would like ongoing open-label access to Truvada for HIV prevention, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
iPrEx was a ground-breaking multinational study showing that daily PrEP using tenofovir plus emtricitabine reduced the risk of sexual transmission of HIV among gay and bisexual men by 42%, rising to 92% for those with measurable blood drug levels. After the randomized phase of the trial, participants had the opportunity to join the Open-Label Extension (OLE) study, looking at longer-term outcomes.
iPrEx principle investigator Robert Grant discussed findings from the OLE at a press conference prior to his late-breaker presentation during the final session of the conference.
[Robert Grant speaks at IAS 2013 press conference, Kuala Lumpur, July 3, 2013]
R Grant, V McMahan, R Amico, et al. Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). Kuala Lumpur, June 30-July 3, 2013. Abstract WELBC02.